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eativecommons.org/licenses/by-nc-Summary Background: The purpose of this study was to determine whether the mucosal
expression of interleukin (IL)-23p19 has a role in the pathogenesis of ulcerative colitis, and
to determine its relation to disease severity.
Methods: This study was performed on 50 patients with ulcerative colitis and 10 normal individ-
uals as the controls. They were divided into Group I (27 patients with mild to moderate disease),
Group II (23 patients with severe disease), and Group III (10 normal individuals). All patients and
the controls were subjected to histopathological study, IL-23p19 immunohistochemical stain-
ing, IL-23R expression by flow cytometry, and serum IL-23 by enzyme-linked immunoassay.
Results: There was a significant increase in IL-23p19 gene expression and IL-23R level in pa-
tients with ulcerative colitis, compared to the controls. A significant positive correlation was
detected between increased expression of the IL-23p19 gene, IL-23R, high serum IL-23, and
the severity of the disease.
Conclusion: Increased expression of the IL-23p19 gene has a role in the pathogenesis of ulcer-
ative colitis. Targeted therapy directed against IL-23p19 may be effective in its treatment.
Increased expression of the IL-23p19 gene and IL-23R with high serum IL-23 is correlated posi-
tively with disease severity.
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Inflammatory bowel disease consists of two distinct dis-
eases: Crohn’s disease (CD) and ulcerative colitis (UC). Both
diseases may arise because of the combination of genetic
variations and alterations in bacterial flora that can sub-
sequently drive a dysregulated immune response that re-
sults in chronic intestinal inflammation [1,2].
Interleukin (IL)-23 is a member of a small family of
proinflammatory cytokines, consisting of a p19 subunit and
a common p40 subunit that is shared with IL12 [3]. The
receptor for IL-23 (IL-23R) consists of the IL-12R beta 1
subunit and a novel component termed “IL-23R” [4], which
is expressed predominantly on T cells, natural killer (NK)
cells, and natural killer T (NKT) cells, and to a smaller
extent on monocytes, macrophages, and dendritic cells
(DCs) [5]. Interleukin 23 has a crucial role in the patho-
genesis of several immune-mediated inflammatory diseases
by recruiting several inflammatory cells and Th17 cells
[6,7]. Interleukin 23 promotes Th17 cells in producing
tumor necrosis factor alpha (TNFa), IL-17, IL-6, IL-22,
granulocyte-macrophage colony-stimulating factor, and
other novel factors, which are associated with the induc-
tion of autoimmune inflammation [6,8,9]. This study was
performed to determine whether the mucosal expression of
IL-23p19 has a role in the pathogenesis of UC and to
elucidate its relation to disease severity.
Materials and methods
Patients and methods
This study was performed on 50 patients with UC and 10
individuals (i.e., the controls) for whom colonoscopic and
histopathologic findings were normal. This study was
accepted by the medical ethics committee of the Faculty of
Medicine at Tanta University (Tanta, Egypt). Each patient
provided written consent after they received a complete
explanation of the protocol of the study. The studied pa-
tients were selected from the inpatient and outpatient
clinics of the Tropical Medicine and Internal Medicine De-
partments of the Tanta University Hospital (Tanta, Egypt) in
the period between November 2012 and October 2013. Ul-
cerative colitis patients were diagnosed on the basis of
clinical, endoscopic, and histological manifestations ac-
cording to the criteria of the American Gastroenterology
Association [10]. The patients were divided, based on
endoscopic and histopathological findings, into Group I (27
patients with mild to moderate UC disease), Group II (23
patients with severe UC disease), and Group III (10 in-
dividuals whose colonoscopic and histopathologic findings
were normal as control). Patients in the following cate-
gories were excluded from the study: patients who were
pregnant; patients who had a malignancy, heart failure,
renal failure, thyroid disorders, acute infection, or stroke;
and patients taking immunosuppressive drugs.
All patients and controls were subjected to a complete
history taking and thorough clinical examination. Labora-
tory investigations such as complete blood picture, blood
urea and serum creatinine, erythrocyte sedimentation rate,
and stool examination were performed to exclude bacterialcauses of colitis. Colonoscopy was performed in all groups
and the severity of the disease was determined. The
endoscopic scoring system for UC by Pineton de Chambrun
et al [11] was used, as follows: Score 0, normal or inactive
disease; Score 1, mild disease (i.e., erythema, decreased
vascular pattern, and mild friability); Score 2, moderate
disease (marked erythema, increased vascular pattern,
friability, and erosion); and Score 3 (severe disease with
spontaneous bleeding and ulceration). Endoscopic findings
were recorded and multiple biopsies were obtained for
histopathology, IL-23p19 immunohistochemical staining,
and IL-23 R expression by flow cytometry.
Histopathological study
Four-micrometer thick serial sections of formalin fixed,
paraffin-embedded tissue were cut and stained using he-
matoxylin and eosin for histopathological evaluation and
grading of the groups. A six grade classification system for
inflammation was used. The grades were: 0, structural
change only; 1, chronic inflammation; 2, lamina propria
neutrophils; 3, neutrophils in the epithelium; 4, crypt
destruction; and 5, erosions or ulcers [12].
Interleukin-23p19 immunohistochemical staining
Four-micrometer thick serial sections of formalin fixed,
paraffin-embedded tissue were cut and mounted on posi-
tively charged glass slides. After incubation at 60C over-
night and deparaffinization, the sections were placed in
0.01M sodium citrate buffer (pH 6.0) and heated twice for
5 minutes in a microwave oven. After inactivation of
endogenous peroxidase with 0.5% metaperiodic acid in
phosphate-buffered saline (PBS) for 10 minutes, the sec-
tions were incubated with 10% horse serum in PBS for
1 hour. The sections were then incubated at 4C overnight
with 100 diluted primary goat antimouse IL-23p19 anti-
body (R&D Systems, Inc., Minneapolis, MN, USA). The
standard avidinebiotinperoxidase complex (ABC) technique
was performed using the LabVision Secondary Detection Kit
(UltraVision Detection System Anti-polyvalent, HRP). The
color was visualized by incubation with chromogen 3,30-
diaminobenzidine for 5 minutes. The slides were then
counterstained with Mayer hematoxylin and cover slipped
with Permount (StatLab, McKinney, TX). Negative controls
without the primary antibodies were set for each test.
Immunohistochemical evaluation
Results were expressed semiquantitatively. Positively
stained cells were counted by examining at least 10 random
fields (200) in each section and expressed as the per-
centage of positive cells over the total cell number [13].
IL-23R expression by flow cytometry
Peripheral blood mononuclear cells
Lymphocytes were isolated from peripheral blood by incu-
bation with Rosette Sep Human CD4þT cells (cytotoxic
T-lymphocytes) enrichment cocktail (Stem Cells Technolo-
gies, Grenoble, France), followed by centrifugation on a
90 H. El-Bassat et al.density gradient (Lymphoprep; PAA, Pasching, Austria).
Lymphocytes were purified by centrifugation through
Lymphoprep.
Peripheral CD4þ. For cellular surface staining the
following antibodies and secondary reagents were used in
different combinations: biotinylated goat antihuman IL-23R
(BAF1400; R&D Systems). Streptavidin-APC (BD Bioscience,
San Jose, CA, USA), CD3-FITC (eBioscience, San Diego, CA,
USA), CD4 PE-Texas Red (Invitrogen, Carlsbad, CA, USA),
CD45RO-FITC (Dako, Glostrup, Denmark), CD45RO-Pacific
Blue (BioLegend, San Diego, CA, USA), CCR6-PE (BD
Bioscience), CD45RA-PE (Invitrogen), CD45RA-PE-Cy7
(eBioscience), plus matched isotypes as controls. Cells
were acquired on a BD FACSAria II (BD Bioscience).
Analysis of fluorescence-activated cell sorting (FACS) data
was performed using FlowJo software (TreeStar, Ashland,
OR. USA).
Lamina propria mononuclear cells
Isolation of intestinal lymphocytes. For intraepithelial
lymphocytes (IEL) isolation, endoscopic procedure was
performed as follows: intestinal tissue were removed and
washed through with cold CMF using a 50 mL syringe fitted
with a short plastic cannula. This removed all food remains
and most mucus. The cleaned intestines were then placed
on CMF-moistened paper towels. After addition of EDTA in
CMF, the guts were incubated at room temperature with a
magnetic stirrer to remove the epithelium. When the
supernatant fluid became sufficiently clouded with cells,
it was removed and fresh EDTA/CMF added (usually every
15 minutes). After approximately 90 minutes, no more cells
were seen in the supernatant, which indicated that all of
the epithelium had been removed. This was confirmed by
histological examination of the remaining fragments. The
pieces were then washed with CMF and incubated for 20
minutes with stirring in 25 mL RPMI/NCS to inactivate any
remaining EDTA. The remaining fragments were then
transferred to flasks containing 15 mL RPMI/NCS
containing collagenase. The flasks and contents were then
incubated at 37C in an orbital incubator (Gallenkamp
typeIH 460) for 90 minutes at 180 cycles/min.
The supernatant from each wash was pooled and poured
through a nylon wool column to enrich T cells and remove
the mucus. The resulting cell suspension was used to
analyze IEL.
Intraepithelial lymphocytes. The IEL suspensions con-
taining approximately 1 105 cells eachwere resuspended in
cold PBS and stained with Aqua Live/Dead cell discriminator
(Invitrogen; catalog no. L34597) in accordance with the
manufacturer’s protocol. Cells were then stained for 1 hour
in the dark at 4C with optimized concentrations of anti-CD3
Alexa750-APC (eBioscience; clone 17A2), anti-CD8
Alexa700 (eBioscience; clone 53-6.7), anti-CD4 Pacific Blue
(eBioscience; clone RM4-5), anti-TCR GD R-PE (BD
Bioscience; Pharmingen clone GL3), and biotinylated
polyclonal anti-IL-23R (BAF1686; R&D Systems). Cells were
washed twice with PBS containing 1% bovine serum albumin
(FACS) buffer). Cells were then stained for 1 hour with
streptavidin-conjugated Qdot 605 (Q10101MP; Invitrogen).Stained cells were washed once in FACS buffer and
subsequently fixed in 4% formalin for 1 hour. The cells were
then washed once and resuspended in FACS buffer and
analyzed using an LSR II flow cytometer (Becton Dickinson,
San Jose, CA). The data were analyzed by using FlowJo
software (Treestar, Inc., Ashland, OR). Gates were set on
singlets and then on live lymphocytes. Subsequent gates
were based on Fluorescence-Minus-One and unstained
controls.
Serum IL-23 by enzyme-linked immunosorbent assay
IL-23 cytokine level was assayed using a commercially
available IL-23 enzyme-linked immunosorbent assay (ELISA)
kit (R&D Systems) according to the manufacturer’s
instructions.Statistical analysis
The statistical data are reported as the mean  standard
deviation (SD), frequencies (number), and percentages
when appropriate. A comparison of numerical variables
between the study groups was performed using Man-
neWhitney U test to compare independent samples from
the two groups. The one-way analysis of variance test was
used to compare between more than two groups when the
data were normal and the KruskaleWallis test was used
when the data were not normal. Qualitative data was
compared using the Chi-square test. Spearman’s rank cor-
relation was used to quantify the association between
continuous or ordered categorical variables. A p < 0.05 was
statistically significant. All statistical calculations were
performed using the computer program SPSS version 15 for
Microsoft Windows (Statistical Package for the Social Sci-
ence; SPSS, Chicago, IL, USA).Results
Clinical and laboratory data of the studied groups
Significantly higher levels of ESR and disease duration were
detected in patients with severe disease, compared to
patients with mild to moderate UC disease (p < 0.05).
Abdominal pain, diarrhea, blood in the stool, and ESR were
significantly higher in UC patients, compared to the con-
trols (Table 1).Histopathological evaluation and correlation with
endoscopic groups
The 50 studied patients with UC showed different grades of
severity: 5 (10%) patients were Grade 0; 12 (24%) patients
were Grade 1; 8 (16%) patients were Grade 2; 15 (30%) pa-
tients were Grade 3 (Figure 1A); 6 (12%) patients were Grade
4 (Figure 1B); and only four (8%) patients were Grade 5
(Figure 1C). In correlation with the endoscopic grouping, the
Group I patients were distributed among Grades 0e3,
whereas the Group II patients were distributed among
Grades 2e5 with statistical significance (pZ 0.02) (Table 2).
Table 1 Clinical and laboratory data of the studied groups.
Parameters Mild to moderate
UC Group I
(n Z 27)
Severe UC
Group II
(n Z 23)
Control Group
Group III
(n Z 10)
p
Age (y) 36.1  13.4 41.5  12.7 35.2  12.8 0.270
Sex (m/f) 16/11 14/9 6/4 1.000
Disease duration (y) 2.6  1.7 4.2  3.1 a d 0.042 a
Abdominal pain 20/27 18/23 3 b 0.083
Diarrhea 18/27 19/23 2 b 0.017 *
Blood in stool 19/27 21/23 d 0.111
ESR (mm/h) 21.8  7.9 33.6  8.5 a 10.9  1.9 b <0.001 *
Hb (gm/d) 12.1  1.3 11.6  1.6 12.6  1.5 0.197
* Indicates p < 0.05 between all groups.
Group I, patients with mild to moderate disease; Group II, severe disease; Group III, no disease (normal control).
UC Z ulcerative colitis; ESR Z erythrocyte sedimentation rate; Hb Z hemoglobin.
a Significant difference between Group I and Group II.
b Significant difference between patients and the controls.
Figure 1 Histopathological grades of ulcerative colitis shows (A) Grade 3, neutrophilic infiltrate in the epithelial cells; (B) Grade
4, crypt destruction; and (C) Grade 5, erosions and ulcers (hematoxylin and eosin stain).
Table 2 Correlation between histological grading and endoscopic severity in the ulcerative colitis (UC) patients.
Studied groups Histopathological grading p
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Mild to moderate
UC Group I
(n Z 27)
5 12 6 4 0 0 0.02 *
Severe UC
Group II
(n Z 23)
0 0 2 11 6 4
* Indicates a significant value, p < 0.05.
Group I, patients with mild to moderate disease; Group II, severe disease; Group III, no disease (normal control).
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expression in the studied groups
Table 3 shows a significant increase in the serum level of IL-
23 and IL-23R expression in peripheral blood and in lamina
propria lymphocyte (CD4) in the UC patient group,
compared to the control group. This increase was greater in
patients with severe disease, compared to patients with
mild to moderate disease. Immunohistochemical evaluationof IL-23p19 showed that was expressed in the lamina
propria macrophages. The mean number of cells expressing
IL-23p19 in Group I was 11.6  3.4 (Figure 2A) and in Group
II was 19.6  5.5 (Figure 2B). The difference was statisti-
cally different between the two groups. By contrast, the
number of cells was only 3.5  1.6 in Group III (i.e., the
control group; Figure 2C). The difference between the
three groups was statistically significant. Based on flow
cytometry analysis, IL-23R was highly expressed in the
Table 3 IL-23R expression, serum IL-23, and IL-23p19 expression in the studied groups.
Parameters Mild to moderate UC
Group I (n Z 27)
Severe UC Group II (n Z 23) Control group
Group III (n Z 10)
p
IL-23 R expression %
PBMC 6 12 1 0.037 *
LPMC 20 29 6 0.001 *
S IL-23 (pg/mL) 48.9  7.6 137.4  45.5 24.2  9.4 <0.001 *
IL-23 p 19 expression
Immunohistochemistry % of þve cells
11.6  3.4 19.6  5.5 3.5  1.6 <0.001 *
* Indicates p < 0.05, between all groups.
Group I, patients with mild to moderate disease; Group II, severe disease; Group III, no disease (normal control).
IL Z interleukin; LPMC Z lamina propria mononuclear cells (i.e., lymphocytes); PBMC Z peripheral blood mononuclear cells (i.e.,
lymphocytes); UC Z ulcerative colitis.
Figure 2 Immunohistochemical expression of IL23p19 in the ulcerative colitis groups shows (A) mild expression in Group I, (B)
extensive expression in Group II, and (C) very minimal expression in Group III.
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mild lesions in Group I (Figures 3 and 4); this difference is
highly statistically significant.Correlation between endoscopic severity,
histopathological grading, and studied parameters
in UC patients
Table 4 shows a significant positive correlation between
endoscopic severity and histological grading of UC with IL-
23p19 expression (r Z 0.591, p Z 0.038; and r Z 0.612,Figure 3 In PBMC and LPMC, IL23R is mildly increased in Group
PBMC Z peripheral blood mononuclear cell.p Z 0.047, respectively), IL-23R expression (r Z 0.542,
p Z 0.015; and r Z 0.526, p Z 0.031, respectively), and
serum level of IL-23 (rZ 0.637, pZ 0.024; and rZ 0.551,
p Z 0.019, respectively).Discussion
Patients with UC are at increased risk of inflammation.
Interleukin-23 is a newly identified cytokine with increased
expression in inflamed biopsies of colon mucosa in patients
with CD; however, there is inconsistent evidence on its roleI. IL Z interleukin; LPMC Z lamina propria mononuclear cell;
Figure 4 In PBMC and LPMC, IL23R is highly increased in Group II. IL Z interleukin; LPMC Z lamina propria mononuclear cell;
PBMC Z peripheral blood mononuclear cell.
Table 4 Correlation between endoscopic severity, histopathological grading, and the studied parameters in ulcerative colitis
patients.
Parameters IL-23p19 expression IL-23 R expression Serum IL-23
R p R p R p
Endoscopic severity 0.591 0.038 * 0.542 0.015 * 0.637 0.024 *
Histopathological grade 0.612 0.047 * 0.526 0.031 * 0.551 0.019 *
* Indicates p < 0.05.
IL Z interleukin; UC Z ulcerative colitis.
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shows similar function as IL-12 in promoting cellular im-
munity and enhancing lymphocyte proliferation [15].
This study showed significant increased expression of the
IL-23p 19 gene in patients with UC, compared to the con-
trols. This increase was significantly higher in patients with
severe UC disease, compared to patients with mild to
moderate disease. This was similar to the results reported
by Schmidt et al [16], Zhanju et al [13], and Kobayashi et al
[17]. We observed that, based on immunohistochemistry,
IL-23p19-positive cells were primarily macrophages. This
was in agreement with the findings of Zhanju et al [13].
These findings suggest that IL-23 is produced by intestinal
mucosal macrophages in the inflamed mucosa of UC pa-
tients [13]. On stimulation by bacterial ligand, IL-23 is
produced by antigen-presenting cells. After binding to an
appropriate receptor (i.e., IL-23R), this cytokine can stim-
ulate the production of IL-17, TNFa, and IL-6 from T cells.
Interleukin-17 stimulates the expression of adhesion mol-
ecules such as ICAM-1 on endothelial cells, and stimulates
the release of IL-6 and IL-8 from myofibroblast and
epithelial cells. Interleukin-8 acts as a chemotactic factor
for neutrophil influx into the intestines. Inflammatory
neutrophils release inflammatory mediators such as matrix
metalloproteinase and inducible nitric oxide. This sequelae
of pathogenic events lead to the chronic inflammation and
epithelial cell damage associated with the disease [18].
Therefore, IL-23 was proposed to have an integral role in
the pathogenesis of inflammatory bowel disease [19].
The present study showed increased expression of IL-23R
in the peripheral blood and in the mucosal biopsy ofsamples from UC patients was significant, compared to the
control group. This increased expression was higher in pa-
tients with severe disease, compared to patients having
mild to moderate disease. In addition, Zhanju et al [13]
demonstrated significant increased expression of IL-23R in
the peripheral blood and mucosal lamina propria cells.
In accordance with the findings reported by Mohammadi
et al [14] and Zheng et al [20], we demonstrated increased
serum level of IL-23 in UC patients, compared to the con-
trols. In addition, the increased serum levels of IL-23 were
greater in patients with severe disease than in patients with
mild to moderate disease. Furthermore, this study reported
a significant positive correlation between high serum IL-23
levels and endoscopic severity of the disease. These find-
ings support the hypothesis that, increased IL-23 levels
reflect the activity of T helper 17 cells in patients with UC
and that IL-23 participates in the pathogenesis of the dis-
ease [20]. In the current study, the increased expression of
IL-23p19 and IL-23 R were significantly and positively
correlated with the endoscopic severity of the disease.
These were consistent with the findings of Schmidt et al
[16] and Zhanju et al [13]. In agreement with experimental
studies of Daniel et al [21] and Ando et al [22], there was a
significant positive correlation between histopathological
severity and the expression of IL-23p19 and IL-23R in the
mucosa of UC patients. Furthermore the severity of histo-
pathological lesions was significantly correlated with serum
IL-23, a finding that was similar to the findings of an
experimental study by Sheikh et al [23].
We conclude that the increased expression of IL-23p19
has a role in the pathogenesis of UC; therefore, targeted
94 H. El-Bassat et al.therapy directed against IL-23p19 may have a therapeutic
role in treating the disease. The increased expression of IL-
23p19, IL-23R, and serum IL-23 are correlated with disease
severity. A limitation of this study was the small number of
the patients. Further studies on a larger population and on
patients under treatment are needed.
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